Alzheimer's disease (AD) is one of the most common neurodegenerative diseases today. The therapy for this disease is limited to only a few drugs that only alleviate symptoms but do not cure nor significantly modify disease progression. Therefore, continuous research to develop new disease-modifying drugs for new targets is necessary. In recent years, the possibility of targeting various signal molecules involved in the pathophysiology of AD, including glycogen synthase kinase 3 (GSK3) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), has been investigated. The aim of this study is to synthesize and characterize a novel proteolysis-targeting chimera (PROTAC) for the targeted degradation of GSK3β and DYRK1A. The target PROTAC consists of three parts: a ligand for proteins of interest (harmine) and a ligand for E3 ligase (thalidomide) linked by an alkyltriazole linker. To prepare PROTAC, it is necessary to synthesize the appropriate precursors: azide 3, harmine alkyne 6, and the carboxylic acid of thalidomide 5. The synthesis of alkyne 6 is carried out in a single reaction step by alkylation of harmine with propargyl bromide in the presence of a base. Azide 3, a precursor of the alkyltriazole linker, is synthesized in three steps from ethanolamine. The thalidomide derivative 5 is synthesized from 4-hydroxythalidomide and tert-butyl-2-bromoacetate to form an ether 4, from which, in the second step, tert-butyloxycarbonyl protecting group (Boc) is removed with trifluoroacetic acid. Alkyne 6 and azide 3 are connected via a 1,2,3-triazole ring in a single reaction step by Huisgen 1,3-dipolar cycloaddition. The removal of Boc from the amino group of compound 7 gives an amine 8. PROTAC 9 was obtained in the coupling reaction between the carboxylic acid of thalidomide 5 and amine 8 using the coupling reagent HATU. The novel compound is characterized by analytical and spectroscopic methods (1H and 13C NMR, MS, and FT-IR). The SwissADME web tool predicted limited oral bioavailability and blood-brain barrier penetration, based on the physicochemical properties. PROTAC 9 is also predicted to be a CYP inhibitor and a P-glycoprotein substrate. The potential for the degradation of target kinases will be investigated in further studies.